Uppthera Inc. has patented new NLRP3 inflammasome inhibitors potentially useful for the treatment of cancer, metabolic and autoimmune diseases, cardiovascular, inflammatory, neurological, renal and respiratory disorders, among others.

Ensem Therapeutics Inc. has divulged new bicyclic heteroaryl and heterocyclic compounds acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer.

The Scripps Research Institute has discovered new bicyclo[1.1.1]pentane-based DNA topoisomerase inhibitors and antibody-drug conjugates comprising a monoclonal antibody covalently linked to a DNA topoisomerase inhibitor. They are described as potentially useful for the treatment of cancer.

Bolt Biotherapeutics Inc. has prepared and tested new immunoconjugates comprising antibodies covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonists. They are designed for potential use in the treatment of cancer.

Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.

Yuhan Corp. has discovered glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of obesity, diabetes, hypertension, hyperlipidemia, hypoglycemia, coronary artery disease, chronic kidney disease and cardiovascular disorders, as well as hepatic steatosis and alcoholic fatty liver disease.

TYK Medicines Inc. has synthesized cyclin-dependent kinase 4 (CDK4) inhibitors designed for use in the treatment of cancer, infections, and metabolic, inflammatory cardiovascular and inflammatory disorders.

Kyungpook National University has patented peptides targeting ubiquitin thioesterase OTUB1 (OTU1) for the treatment of cancer.

The Institute of Materia Medica Chinese Academy of Medical Sciences and the Peking Union Medical College have reported magnolol/honokiol nitrone derivatives acting as nitric oxide (NO) production inhibitors for the potential treatment of amyotrophic lateral sclerosis, traumatic brain injury, cerebral infarction, autoimmune disease, and respiratory tract and skin inflammation, among others.

Arvinas Operations Inc. has disclosed proteolysis targeting chimera (PROTACs) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a B-cell lymphoma 6 protein (BCL-6)-targeting moiety through a linker with potential for use in the treatment of cancer.